Dizal to challenge J&J with FDA approval for lung cancer drug Zegfrovy

7th July 2025 Uncategorised 0

China’s Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod for Zegfrovy to become the only U.S.-endorsed oral treatment for those with a rare type of non-small cell lung cancer.

More: Dizal to challenge J&J with FDA approval for lung cancer drug Zegfrovy
Source: fierce